Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 13:15:1308822.
doi: 10.3389/fendo.2024.1308822. eCollection 2024.

Burden of psoriasis in young adults worldwide from the global burden of disease study 2019

Yuanchen Zhang  1 , Shuai Dong  1 , Yuan Ma  1 , Yan Mou  1
Affiliations

Burden of psoriasis in young adults worldwide from the global burden of disease study 2019

Yuanchen Zhang et al. Front Endocrinol (Lausanne). .

Abstract

Background: To determine the global burden of psoriasis in young adults, i.e., those aged 15-49, from 1990 to 2019 and predict trends in this burden for 2020 to 2030.

Methods: Age-standardized disease burden indicators and their estimated annual percentage changes were assessed and used to compare the estimated burden between regions. In addition, generalized additive models were used to predict the burden in this population from 2020 to 2030.

Results: From 1990 to 2019, the overall burden of psoriasis in young adults worldwide trended downward, as the age-standardized incidence rate and the age-standardized disability-adjusted life year rate decreased. From 1990 to 2019, there were gender differences in the burden of psoriasis between regions with different Socio-demographic index. Specifically, there was a smaller increase in the burden in young men than in young women in middle- and low-middle-Socio-demographic index areas. In 2019, Western Europe, Australasia, and Southern Latin America had the highest age-standardized incidence rate of psoriasis in young adults, whereas age-standardized disability-adjusted life year rates of psoriasis in young adults were highest in high-income North America. In 2019, the psoriasis burden in young adults was the highest in high-Socio-demographic index areas and the lowest in low-Socio-demographic index regions. We predict that from 2020 to 2030, the incidence rate and disability-adjusted life year rate of psoriasis in all age groups of young adults will continue to decline, but the burden in those aged 30-39 will increase.

Conclusion: From 1990 to 2019, the overall burden of psoriasis in each age group trended downward in this period. We predict that from 2020 to 2030, the burden of psoriasis in those aged 30-39 will increase.

Keywords: ASIR; age-standardized DALY rate; estimated annual percentage change; global disease burden; psoriasis; young adults.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
EAPC of global psoriasis burden of young adults, by Regions. (A) EAPC of age standardized incidence rate (B) EAPC of age standardized DALY rate.
Figure 2
Figure 2
The rate for global psoriasis burden of young adults in 2019, by top 30 country and age group. (A) DALY rate (B) Incidence rate.
Figure 3
Figure 3
Heatmap of rate for global psoriasis burden of young adults in 2019, by country and age group. (A) DALY rate (B) Incidence rate.
Figure 4
Figure 4
The EAPC of global psoriasis burden of young adults from 1990 to 2019, by sex and regions. (A) Age standardized incidence rate (B) age-standardized DALY rate.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol (2004) 135(1):1–8. doi: 10.1111/j.1365-2249.2004.02310.x - DOI - PMC - PubMed
    1. Alves NRM, Kurizky PS, da Mota LMH, de Albuquerque CP, Esper JT, Campos ASC, et al. . Elevated serum IL-6 levels predict treatment interruption in patients with moderate to severe psoriasis: a 6-year real-world cohort study. Bras Dermatol (2024) 99(1):34–42. doi: 10.1016/j.abd.2023.03.002 - DOI - PubMed
    1. Tseng JC, Chang YC, Huang CM, Hsu LC, Chuang TH. Therapeutic development based on the immunopathogenic mechanisms of psoriasis. Pharmaceutics (2021) 13(7):1064. doi: 10.3390/pharmaceutics13071064 - DOI - PMC - PubMed
    1. Ding Y, Li W, Guan X, Liu N, Zhou Y, Li G, et al. . Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study. Clin Transl Sci (2023) 16(10):1803–14. doi: 10.1111/cts.13583 - DOI - PMC - PubMed
    1. Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. Bmj (2020) 369:m1590. doi: 10.1136/bmj.m1590 - DOI - PMC - PubMed

Publication types